Rodriguez-Vida, A., Valderrama, B., Castellano, D., Pinto, A., Mellado, B., Puente, J., . . . Bellmunt, J. (2024). Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): A randomized phase II study.
Citação norma ChicagoRodriguez-Vida, A., et al. Induction Avelumab Followed By Chemoimmunotherapy and Maintenance Versus Chemotherapy Alone As First-line Therapy in Cis-ineligible Metastatic Urothelial Carcinoma (INDUCOMAIN): A Randomized Phase II Study. 2024.
Citação norma MLARodriguez-Vida, A., et al. Induction Avelumab Followed By Chemoimmunotherapy and Maintenance Versus Chemotherapy Alone As First-line Therapy in Cis-ineligible Metastatic Urothelial Carcinoma (INDUCOMAIN): A Randomized Phase II Study. 2024.